Showing results (321-330 of 359) with videos related to
Sort By:
Pageof 36
Nature Neuroscience|February 9, 2016
Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of conceptBarbara Franke, Jason L Stein, Stephan Ripke, et al.Schizophrenia Bulletin|December 31, 2014
Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysisCota Navin Gupta, Vince D Calhoun, Srinivas Rachakonda, et al.Frontiers in Systems Neuroscience|March 29, 2011
A baseline for the multivariate comparison of resting-state networksElena A Allen, Erik B Erhardt, Eswar Damaraju, et al.Brain Sciences|July 27, 2024
Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega AnalysisEamonn Kennedy, Spencer W Liebel, Hannah M Lindsey, et al.Biorxiv : the Preprint Server for Biology|January 30, 2023
Bridging Big Data: Procedures for Combining Non-equivalent Cognitive Measures from the ENIGMA ConsortiumEamonn Kennedy, Shashank Vadlamani, Hannah M Lindsey, et al.The American Journal of Psychiatry|March 28, 2020
The Relationship Between White Matter Microstructure and General Cognitive Ability in Patients With Schizophrenia and Healthy Participants in the ENIGMA ConsortiumLaurena Holleran, Sinead Kelly, Clara Alloza, et al.Molecular Psychiatry|August 3, 2023
Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classificationNaohiro Okada, Masaki Fukunaga, Kenichiro Miura, et al.Molecular Psychiatry|August 18, 2023
Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individualsJunya Matsumoto, Masaki Fukunaga, Kenichiro Miura, et al.Plos One|April 30, 2016
The Ontology for Biomedical InvestigationsAnita Bandrowski, Ryan Brinkman, Mathias Brochhausen, et al.Journal of Clinical Psychopharmacology|April 8, 2025
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed ChangesJose de Leon, Ross J Baldessarini, Richard Balon, et al.Pageof 36